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Alzheimer’s disease is a progressive dementia that is characterized by a loss of recent
memory. Evidence has accumulated to support the hypothesis that synapses are critical
storage sites for memory. However, it is still uncertain whether tau protein is involved
in associative memory storage and whether tau is distributed in mature brain synapses.
To address this question, we examined the synaptosomal distribution of tau protein in
both JNPL3 transgenic mice expressing human P301L tau and non-transgenic littermates.
The JNPL3 mouse line is known as one of the mouse models of human tauopathy that
develop motor and behavioral deficits with intracellular tau aggregates in the spinal cord
and brainstem. The phenotype of disease progression is highly dependent on strain back-
ground. In this study, we confirmed that male JNPL3 transgenic mice with C57BL/6J
strain background showed neither any sign of motor deficits nor accumulation of hyper-
phosphorylated tau in the sarkosyl-insoluble fraction until 18 months of age. Subcellular
fractionation analysis showed that both mouse tau and human P301L tau were present
in the synaptosomal fraction. Those tau proteins were less-phosphorylated than tau in
the cytosolic fraction. Human P301L tau was preferentially distributed in the synaptoso-
mal fraction while mouse endogenous tau was more distributed in the cytosolic fraction.
Interestingly, a human-specific tau band with phosphorylation at Ser199 and Ser396 was
observed in the synaptosomal fraction of JNPL3 mice. This tau was not identical to either
tau species in cytosolic fraction or a prominent hyperphosphorylated 64 kDa tau species
that was altered to tau pathology.These results suggest that exogenous human P301L tau
induces synaptosomal distribution of tau protein with a certain phosphorylation. Regulat-
ing the synaptosomal tau level might be a potential target for a therapeutic intervention
directed at preventing neurodegeneration.
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INTRODUCTION
Neurofibrillary tangles (NFTs) and neuronal loss are commonly
observed in neurological disorders, including Alzheimer’s disease
(AD) and other tauopathies (1–3). Brain regions showing dys-
function overlap those displaying NFTs and neuronal loss (4),
suggesting that mechanisms of NFT formation and neuronal loss
may underlie neuronal dysfunction of affected brain areas. In
frontotemporal dementia with Parkinsonism linked to tau on
chromosome 17 (FTDP-17-tau), tau gene mutations induce NFT
formation and neuronal loss (5–8), suggesting that dysregulation
of tau may be a cause of NFT formation and neuronal death. This
notion is supported by some reports showing that overexpression
of FTDP-17-tau mutant tau induces NFT formation, neuronal
loss, and behavioral abnormalities. In the mouse model rTg4510
overexpressing P301L mutant tau under the regulation of tetracy-
cline, inhibition of mutant tau overexpression in the disease state
blocked neuronal death and reversed memory impairment but
still induced NFT formation (9), suggesting that NFTs themselves
are not toxic, but the mechanism of neuronal death and memory
impairment may underlie the process of NFT formation. Although
the initial molecular event of tau pathogenesis remains unclear, the
hyperphosphorylation of tau is strongly correlated with the sever-
ity of the pathology (10). The existence of hyperphosphorylated
tau oligomers in human AD brain and transgenic mouse brains
supports the idea of neurotoxic tau species (11–15).
Recently, several groups reported the mislocalization of hyper-
phosphorylated tau into dendritic spines (16–20). Interacting
with Fyn kinase, tau contributes to NMDA stabilization (17, 21).
Although a novel function of tau in post-synaptic regions was
observed, evidence of hyperphosphorylated tau in dendritic spines
still requires conclusive confirmation. On the other hand, it is
well known that tau is involved in axonal transport stabilization
and promotion of microtubule polymerization, and it partici-
pates in the transport of vesicles and organelles from axons to
synaptic terminals (22). It was also reported that tau overexpres-
sion affects axonal transport by obstructing kinesin movement on
microtubules (23–26). Since axon was labeled with Tau1 antibody,
which recognizes non-phosphorylated tau at Ser199 (27), axonal
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tau seems to be de-phosphorylated. Therefore, it is important to
clarify the status of tau phosphorylation in synaptic regions. In
this study, we investigated the biochemical properties of synap-
tosomal tau extracted from transgenic mice expressing human
P301L mutant tau.
MATERIALS AND METHODS
JNPL3 MICE AND LITTERMATES
Male hemizygous JNPL3 mice were obtained from Taconic Labs
(Germantown, NY, USA) at 8 weeks of age. JNPL3 mice express
4R0N isoform of human P301L mutant tau and are character-
ized as developing NFT, as well as sarkosyl-insoluble tau in an
age-dependent manner (28, 29). Transgenic (Tg) mice and non-
Tg littermates were bred by mating hemizygous JNPL3 mice with
C57BL/6J Jcl (Clea, Tokyo, Japan). The mice were genotyped for
the tau transgene by PCR between exons 9 and 13 of human
tau cDNA. They were housed under controlled conditions with
a 12-h day/night cycle. The age range of both male JNPL3 (n= 8)
and male non-Tg mice (n= 5) was 15.7–18.5 months. Procedures
involving animals and their care were approved by the Animal Care
and Use Committee of RIKEN.
TISSUE EXTRACTION AND SUBCELLULAR FRACTIONATION
Mice were euthanized by cervical dislocation to preserve the brain
metabolic environment and prevent artifacts that could alter tau
biochemical profiles. Brains were quick-frozen on dry ice and
stored at −80°C. For sarkosyl extraction, the cerebral cortex con-
taining the hippocampus of the left hemibrain was subsequently
homogenized in five volumes of Tris–buffer saline (TBS) con-
taining protease and phosphatase inhibitors [25 mM Tris/HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5 mM sodium
pyrophosphate, 30 mM β-glycerophosphate, 30 mM sodium flu-
oride, and 1 mM phenylmethylsulfonyl fluoride (PMSF)]. The
homogenates were centrifuged at 27,000× g for 20 min at 4°C
to obtain the supernatant and pellet fractions. Pellets were re-
homogenized in five volumes of high salt/sucrose buffer (0.8 M
NaCl, 10% sucrose, 10 mM Tris/HCl, pH 7.4, 1 mM EGTA, 1 mM
PMSF) and centrifuged as above. The supernatants were collected
and incubated with sarkosyl (Sigma, St. Louis, MO, USA; 1%
final concentration) for 1 h at 37°C, followed by centrifugation
at 150,000× g for 1 h at 4°C to obtain salt and sarkosyl-soluble
and sarkosyl-insoluble pellets. The pellets were re-suspended in
TE buffer (10 mM Tris/HCl, pH 8.0, 1 mM EDTA) to a volume
equivalent to wet weight of the original tissue. For subcellu-
lar fractionation, fractions were prepared as previously described
(30). Briefly, the cerebral cortex containing the hippocampus of
the right hemibrain was Dounce-homogenized with 15 strokes
in 10 volumes of homogenization buffer [25 mM Tris/HCl, pH
7.4, 9% sucrose, 2 mM EDTA, 5 mM dithiothreitol, 5 mM 4-
(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF),
5 ng/ml Antipain, 2 ng/ml aprotinin, 5 ng/ml leupeptin, 5 ng/ml
pepstatin A, 1µM okadaic acid, 1 mM NaF, 1 mM Na3VO4].
Nuclei (P1) were removed by 5 min centrifugation at 1,000× g.
The supernatant was subjected to 12,500× g centrifugation for
15 min to yield the crude synaptosomal fraction (P2). The super-
natant was centrifuged for 1 h at 176,000× g, resulting in cytosol
(S3) and light membrane and Golgi (P3) fractions. Synaptosomal
fraction P2 was lysed hypo-osmotically and spun for 20 min at
25,000× g to obtain the synaptosomal membrane fraction LP1.
The supernatant was centrifuged for 2 h at 176,000× g, resulting in
a synaptic vesicle-enriched fraction (LP2) and a supernatant (LS2).
ANTIBODIES
E1 (31), a polyclonal antibody specific to human tau (aa 19-33,
unphosphorylated), was prepared in our laboratory. MS06, a poly-
clonal antibody specific to mouse tau, was raised against mouse
tau polypeptide corresponding to amino acid residue 118–131
(SKDRTGNDEKKAKG). Tau5, pS199, pT231, and pS396 were
purchased from Biosource International (Camarillo, CA, USA).
Tau1 was from Chemicon (Temecula, CA, USA). Monoclonal
antibodies to β-actin and β-tubulin were purchased from Sigma.
Monoclonal antibodies to GAP-43, PSD-95, and synaptotagmin
were purchased from BD Transduction Laboratories (San Jose,
CA, USA). For western blotting, antibodies were used at the fol-
lowing dilutions in blocking solution: E1, 1:5,000; MS06, 1:2,000;
Tau1, 1:5,000; Tau5, 1:2,000; pS199, 1:5,000; pT231, 1:2,000; pS396,
1:2,000; β-actin, 1:5,000; β-tubulin, 1:5,000; GAP-43, 1:2,000;
PSD-95, 1:2,000; synaptotagmin, 1:2,000.
WESTERN BLOTTING
Fractionated tissue extracts were dissolved in sample buffer con-
taining β-mercaptoethanol (0.01%). The samples were separated
by gel electrophoresis on 10 or 5–20% gradient SDS-PAGE gels
(Wako Pure Chemical Industries, Osaka, Japan), and transferred
to nitrocellulose membranes (Schleicher & Schuell BioScience,
Dassel, Germany). To estimate protein molecular weights, mol-
ecular size markers (Precision Plus Protein™ Standards, Bio-Rad
Laboratories, Hercules, CA, USA; MagicMarker™ XP Western
Protein Standard, Life Technologies, Carlsbad, CA, USA) were
loaded on each gel. After blocking with a blocking solution con-
taining 5% non-fat milk, 0.1% goat serum, and 0.1% Tween-20
in PBS, the membranes were incubated with various antibod-
ies, washed to remove excess antibodies, and then incubated
with peroxidase-conjugated, goat anti-rabbit antibodies (1:5000,
Jackson ImmunoResearch, West Grove, PA, USA) or anti-mouse
IgG (1:5000, Jackson ImmunoResearch). Bound antibodies were
detected using an enhanced chemiluminescence system, SuperSig-
nal West Pico (Pierce Biotechnology, Rockford, IL, USA). Quan-
titation and visual analysis of immunoreactivity were performed
with a computer-linked LAS-3000 Bio-Imaging Analyzer System
(Fujifilm, Tokyo, Japan) using the software program Image Gauge
3.0 (Fujifilm).
STATISTICAL ANALYSIS
Statistical analyses were conducted using PRISM4 (GraphPad
Software Inc., La Jolla, CA, USA). Data were analyzed using the
Friedman test or two-way ANOVA, unless otherwise noted.
RESULTS
EXAMINATION OF SARKOSYL-INSOLUBLE TAU IN MALE JNPL3 MICE
Hemizygous JNPL3 mice were reported to develop motor and
behavioral deficits, initially presenting with hind-limb dysfunction
starting at 6.5 months (28). These phenotypes were shown with a
mixed C57BL/DBA2/SW strain background and mostly in female
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mice. Biochemically, subcortical regions contained more sarkosyl-
insoluble tau than cortico-limbic regions, and male mice had less
sarkosyl-insoluble tau than age-matched female mice (29). More-
over, a previous study showed that JNPL3 mice with C57BL/6J
strain background significantly slowed the progression of tau
pathology (32). In agreement with these reports, male hemizy-
gous JNPL3 mice on an in-bred C57BL/6J strain at 15–18 months
of age did not show any sign of motor deficits. To confirm whether
male JNPL3 mice developed pathological tau aggregates in their
brains, a sarkosyl-insoluble fraction was prepared using the sarko-
syl extraction protocol as previously described (15, 29). Human
and mouse tau proteins were detected in the TBS-soluble frac-
tion using anti-human tau-specific antibody E1, anti-mouse tau-
specific antibody MS06, and Tau5 antibody recognizing both tau
(Figure 1A). We observed variable degrees of human tau protein
among individual JNPL3 mice when normalized with GAPDH
level (Figure 1A). In sarkosyl-insoluble fractions from male JNPL3
brains, the hyperphosphorylated tau migrating at 64 kDa was not
found, although variable levels of 50 kDa tau bands were detected
in this fraction (Figure 1B). The hyperphosphorylated 64 kDa tau
was a marker of tau pathology in symptomatic JNPL3 and rTg4510
mice expressing the 4R0N isoform of human P301L mutant tau
(15, 29). Because of undetectable levels of 64 kDa tau in male
JNPL3 cerebral cortices (Figure 1B), these male JNPL3 cerebral
cortices were considered to likely contain very few pathological
tau inclusions.
SUBCELLULAR DISTRIBUTION OF TAU PROTEIN IN JNPL3 MICE
To identify tau protein in a synaptosomal fraction, we first per-
formed subcellular fractionation and organelle enrichment by
basic differential centrifugation protocol (30) (Figure 2A). As a
result, pre-synaptic markers (GAP-43, synaptotagmin) and post-
synaptic marker (PSD-95) were mostly distributed in the crude
synaptosomal (P2) fraction (Figure 2B). Tau was recovered at
equal ratios in the nuclear (P1), P2, and cytosolic (S3) frac-
tions (Figure 2C). Distributions of tau, β-actin and β-tubulin in
each fraction were similar in JNPL3 mice and non-Tg littermates
(Figures 2B,C). Interestingly, the proportion of the tau level in
S3 fraction was significantly lower than that of the β-tubulin level
in S3 fraction (Figure 2C, tau and β-tubulin in S3 from JNPL3
were 30.2 and 41.7%, respectively, p< 0.05; tau and β-tubulin
in S3 from non-tg were 31.2 and 44.9%, respectively, p< 0.01).
This suggests that tau may have distinct functions rather than
that of microtubule-association property. To further characterize
the synaptosomal fraction, P2 fraction was lysed hypotonically
and divided by differential centrifugation to obtain synaptosomal
membrane (LP1), synaptic vesicle (LP2), and soluble synaptoso-
mal (LS2) fractions (Figure 2A). GAP-43, synaptotagmin, and
PSD-95 were mostly distributed in LP1 fraction (Figure 2B). Some
of the synaptotagmin immunoreactivity was detected in LP2 as a
synaptic vesicle protein (Figure 2B). Interestingly, abundant levels
of both human and mouse tau were detected in LP1 but not in
LP2 fraction (Figure 2B). Similar to the proportions of tau and
β-tubulin S3 fraction, the proportion of the tau level in LP1 frac-
tion was significantly higher than that of the β-tubulin level in LP1
fraction (Figure 2D, tau and β-tubulin in LP1 from JNPL3 were
77.9 and 39.4%, respectively, p< 0.001; tau and β-tubulin in LP1
FIGURE 1 | Soluble and sarkosyl-insoluble tau in JNPL3 male mice.
(A) Western blots of TBS-soluble tau in mouse cerebral cortices. Equal
volumes of TBS-soluble fraction derived from 0.2 mg wet weight of brain
from eight male JNPL3 and two male non-tg mice were separated by
SDS-PAGE, blotted, and then probed with E1, Tau5, MS06, and GAPDH
antibodies. (B) Western blot of sarkosyl-insoluble fractions in mouse
cerebral cortices. Samples derived from 20 mg wet weight from male
JNPL3 and non-tg mice, 5 mg wet weight from female JNPL3 cortex (ctx),
and 2.5 mg wet weight from female JNPL3 spinal cord (SPc) were
separated by SDS-PAGE, blotted, and then probed with E1 antibody.
from non-tg were 75.1 and 36.0%, respectively, p< 0.001). Again,
tau may have a function that is not related to the microtubule-
association. Furthermore, tau proteins in P1, P2, P3, and LP1
fractions had migrated faster than that in S3 fraction (Figure 2B,
Tau5 and E1 blots), suggesting that posttranslational modifica-
tion of those tau proteins was different from that of cytosolic tau
protein.
TAU IN SYNAPTOSOMAL FRACTION
To examine the effect of transgenic tau expression in the synap-
tosomal fraction, we next analyzed the protein property of tau in
LP1 fraction. A panel of tau antibodies (E1, Tau5, MS06, Tau1,
pS199, pT231, and pS396) confirmed the difference in band pat-
tern between S3 and LP1 fractions (Figures 3A and 4A,B). When
tau phosphorylations at the sites of Ser199, Thr231, and Ser396
were compared, those sites in LP1 were less-phosphorylated than
in S3 fraction (Figures 3B,C). Tau1 antibody confirmed a higher
level of de-phosphorylated tau in LP1 fraction than in S3 frac-
tion of both JNPL3 and non-tg mice (Figures 3B,C). The ratio
of tau phosphorylation between S3 and LP1 fractions of non-Tg
mouse brain was similar to that of JNPL3 mouse brain [JNPL3,
ratio of LP1/S3= 1.24 (Tau1), 0.40 (pS199), 0.36 (pT231), 0.42
(pS396); non-tg, ratio of LP1/S3= 1.16 (Tau1), 0.33 (pS199), 0.36
(pT231), 0.43 (pS396)] (Figures 3B,C). Total tau level in LP1 frac-
tion from non-tg mice was also lower than that in S3 fraction
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FIGURE 2 | Subcellular fractionation of mouse cerebral cortex.
(A) Schematic representation of the subcellular fractionation steps. P1,
nuclear pellet and debris; P2, crude synaptosomal fraction; P3, light
membranes; S3, cytosolic fraction; LP1, synaptosomal membrane fraction;
LP2, synaptic vesicle-enriched fraction; LS2, soluble synaptosomal fraction.
(B) Western blots of JNPL3 and non-tg male mouse cerebral cortex
subcellular fractions. P1, P2, P3, or S3 fraction derived from 0.13 mg wet
weight of tissue and LP1, LP2, or LS2 fraction derived from 0.5 mg wet
weight of tissue were loaded on SDS-PAGE. Blots were probed with PSD-95,
synaptotagmin, GAP-43, Tau5, E1, β-tubulin, and β-actin antibodies.
(C) Proportions of protein levels in fractions (P1, P2, P3, and S3) of tau (Tau5)
and β-tubulin (β-tub) from JNPL3 (n=5) and non-tg (n=5) mice are shown.
Intensities of tau (49–65 kDa) and β-tubulin (50 kDa) were measured by
Bio-Imaging Analyzer System. Ratios were indicated by percent of total
(P1+P2+P3+S3). Results are expressed as mean±SEM. (D) Proportions
of protein levels in synaptosomal fractions (LP1, LP2, and LS2) of tau (Tau5)
and β-tubulin (β-tub) from JNPL3 (n=5) and non-tg (n=5) mice were
indicated. Intensities of tau (49–65 kDa) and β-tubulin (50 kDa) were measured
by Bio-Imaging Analyzer System. Ratios were indicated by percent of total
(LP1+LP2+LS2). Results are expressed as mean±SEM.
[Tau5, LP1/S3= 0.37] (Figure 3C). Although tau phosphoryla-
tions at the sites of Ser199, Thr231, and Ser396 in LP1 fraction
of JNPL3 mice was clearly less than those in S3 fraction, mouse
tau phosphorylation in LP1 fraction might be reduced at a few
sites. Further analysis will be needed to determine differential
phosphorylation sites in S3 and LP1 fractions of non-tg mice.
In JNPL3 mice, more human P301L mutant tau was detected
in LP1 fraction than in S3 fraction (Figures 3A,B). In contrast, the
total tau level including both human P301L tau and mouse tau
was higher in S3 fraction than in LP1 fraction (Figures 3A,B).
The higher level of human P301L tau was further confirmed
by the lower level of mouse tau in LP1 fraction than in S3
fraction as detected by mouse tau-specific tau antibody MS06
(Figures 3A,B). These data indicate that the distribution of
human P301L tau in the synaptosomal fraction is greater than
in the cytosolic fraction while that of mouse tau is greater
in the cytosolic fraction than in the synaptosomal fraction. It
should be noted that Tau5 immunoreactivity in LP1 fraction of
JNPL3 mice was more than twofold that of non-Tg mice (2.6-
fold) while Tau5 immunoreactivity in S3 fraction of JNPL3 mice
was less than twofold that of non-tg mice (1.3-fold). This fur-
ther suggests the greater distribution of human P301L tau in
LP1 fraction than in S3 fraction. Taken together, our biochem-
ical analysis of the subcellular fraction revealed the existence of
transgenic human P301L tau in the synaptosomal fraction with
less-phosphorylation.
PHOSPHORYLATED HUMAN P301L TAU IN SYNAPTOSOMAL FRACTION
Although the levels of tau phosphorylation in JNPL3 mice were
similar to those in non-tg mice, we compared western blot pro-
files of tau protein between JNPL3 and non-tg mice. Molecular
weights of major tau bands in S3 and LP1 fractions were esti-
mated by protein standard markers (Figure 4). In S3 fraction
of JNPL3 mice, two bands migrating to 50 and 55 kDa were
labeled with tau antibodies E1, Tau5, MS06, pS199, pT231, and
pS396 (Figure 4A). Tau1 antibody labeled the 50 kDa band but
sparsely labeled the 55 kDa band (Figure 4A). Blot profiles of
JNPL3 mice were not so different from those of non-tg mice
(Figure 4A). JNPL3 mice expressed both human 4R0N tau iso-
form and mouse tau isoforms. In addition, it already is known
that 4R0N isoform is most expressed in adult mouse brains (33).
Therefore, the main components of these two bands might be
human and mouse 4R0N tau isoforms, although the possibility
of other mouse tau isoforms being induced by exogenous human
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FIGURE 3 | Quantitative western blot analysis of tau protein. (A) Tau
band patterns in cytosolic (S3) and synaptosomal membrane (LP1)
fractions from four JNPL3 and four non-tg mouse cerebral cortices.
Equal volumes of fractions derived from 0.25 mg wet weight of brain
were separated by SDS-PAGE, blotted, and then probed with Tau5,
MS06, Tau1, pS199, pT231, and pS396 antibodies. (B,C) The relative ratio
of tau protein between S3 and LP1 fractions from JNPL3 (B) and non-tg
(C) mice was measured (n=4 each). Results are expressed as
mean±SEM. The mean value of tau protein in S3 fraction from JNPL3
mice was normalized to one.
tau cannot be excluded. In LP1 fraction, human tau appeared
with 51 and 53 kDa bands (Figure 4B, E1 blot) whereas mouse
tau appeared on 49 and 51 kDa bands (Figure 4B, MS06 blots).
This phenomenon was also seen in blots of pS199 and pS396 anti-
bodies (Figure 4B, 51 and 53 kDa bands in JNPL3, and 49 and
51 kDa bands in non-tg). The 53 kDa band was labeled with E1,
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FIGURE 4 | Comparison of western blot profiles between JNPL3 and
non-tg mice. (A) Representative blots of S3 fraction stained by tau
antibodies (E1, Tau5, MS06, Tau1, pS199, pT231, and pS396). Molecular
weights were determined by reference standard markers. Two major bands
were migrated to 50 and 55 kDa. Except Tau1 antibody, the 55 kDa band
was more intensely stained than 50 kDa band. (B) Representative blots of
LP1 fraction stained by tau antibodies (E1, Tau5, MS06, Tau1, pS199, pT231,
and pS396). In JNPL3 mouse, two major bands appeared with slower
migration (53 kDa) and faster migration (51 kDa) in E1, Tau5, pS199, and
pS396 blots. Two bands appeared on 49 and 51 kDa in MS06 blot. Three
bands (49, 51, and 53 kDa) appeared in Tau1 blot. Only 51 kDa band
appeared in pT231 blot. In non-tg mouse, 49 and 51 kDa bands appeared in
Tau5, MS06, and Tau1 blots. Three bands (49, 51, and 53 kDa) appeared in
pS199 blot. Only 51 kDa band appeared in pT231 and pS396 blots.
Tau5, Tau1, pS199, and pS396 antibodies, but not with MS06 and
pT231 antibodies. Because of slower mobility in SDS-PAGE, we
expected the 53 kDa band to be more phosphorylated than the
51 kDa band. However, the same size of band was labeled with
Tau1 antibody and not labeled with pT231 antibody, indicating
that this 53 kDa band contained both phosphorylated tau at Ser199
and Ser396 and non-phosphorylated tau at Ser199 and Thr231. In
addition, because the molecular size was quite different from the
hyperphosphorylated 64 kDa tau (Figure 1B), the 53 kDa band
was unlikely to be hyperphosphorylated. Regardless, identifica-
tion of phosphorylation sites and tau isoforms will be necessary
to determine the status of tau phosphorylation and expression in
LP1 fraction.
DISCUSSION
Transgenic mouse models of human neurodegenerative dis-
eases have been developed with the aim of reproducing the
histopathological hallmarks of human diseases. For this pur-
pose, neuropathology and biochemistry were commonly used
for the definition of disease progress. Previous studies express-
ing transgenic tau under the control of neuronal promoters have
successfully shown neuropathological hallmarks with the appear-
ance of motor impairment (28, 34, 35). However, the phenotype
did not completely match with AD because none of these tau
transgenic lines had been comprehensively evaluated in terms
of cognitive performance. Recently, rTg4510 mice were exam-
ined for the association of NFT formation with cognitive func-
tion, demonstrating that suppression of P301L tau expression
reversed behavioral impairments although NFT formation con-
tinued (9). In rTg4510 mice and a neuronal cell culture model
of tauopathy, the mislocalization of tau to dendritic spines was
examined (16). Moreover, a novel function of tau altering Fyn
kinase-mediated NMDA stabilization was reported (17, 21). How-
ever, it is still unclear whether abnormally hyperphosphorylated
tau is accumulated in post-synaptic regions while having a func-
tion of NMDA stabilization. In the present study, instead of
using a mouse model with extremely high expression of P301L
tau, 15- to 18-month-old male JNPL3 mice were examined for
their synaptosomal tau distribution. As previously reported (32),
the hyperphosphorylated 64 kDa tau was barely detectable in
the sarkosyl-insoluble fraction from male JNPL3 mice with a
C57BL/6J strain background. Therefore, our biochemical analy-
sis was unable to determine whether the hyperphosphorylated tau
was distributed in synaptosomal fractions. However, we observed
that less-phosphorylated tau was recovered in the synaptosomal
fraction and that tau distribution was induced by exogenous
human P301L tau expression. Interestingly, the sarkosyl-insoluble
fraction extracted from male JNPL3 mice contained similar less-
phosphorylated tau proteins (Figure 1B). It may be possible that
transition from less-phosphorylation to hyperphosphorylation
takes place in synaptic regions. Further study will be needed to
confirm this possibility.
Among the cytoskeletal proteins showing polarized distribu-
tion, tau is abundantly localized in axons (27, 36–40). Therefore,
it is reasonable to assume that the distribution of tau protein
reaches the axon terminal. In fact, Fein et al. confirmed this by
a flow cytometry method for detecting tau protein in synapses
in AD brain (41). Here, we also showed significant amounts of
tau protein in the synaptosomal fraction by using a subcellu-
lar fractionation method. Interestingly, the tau protein in this
fraction was less-phosphorylated than that in the cytosolic frac-
tion. Our quantitative analysis revealed that non-phosphorylated
tau at Ser199 (detected by Tau1 antibody), as well as transgenic
P301L mutant human tau, was distributed in the synaptosomal
fraction. It was reported that the selective binding of tau to
axonal microtubules was regulated by phosphorylation, as tau
in axons was mostly stained by Tau1 antibody whereas tau in
the cell body and dendrites was stained by AT8 antibody (42).
Therefore, we speculated that P301L mutant human tau was func-
tionally localized in the axon terminal with less-phosphorylation.
In our synaptosome preparation with hypotonic lysis, tau was
mostly recovered in the synaptosomal membrane fraction. As
about 25% of cellular tau is reportedly located in membrane frac-
tions (43), it is quite likely that tau exists in synapse in association
with synaptosomal membrane components. At least, we know
that tau can associate with various other proteins in addition
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to tubulin, including the SH3 domains of Src family tyrosine
kinase (44). Because the synaptosomal membrane fraction con-
tained more Tau1-positive tau than phosphorylated tau, most tau
protein may localize in pre-synaptic regions. In contrast, local-
ization of tau in dendritic spines was confirmed by the use of
co-immunoprecipitation with PSD complex (17) and immunocy-
tochemistry of EGFP-tagged tau expression in primary neuronal
culture (16). In 12-month-old rTg4510 mice, a significant decrease
in the synaptic protein level was biochemically demonstrated (20).
These data strongly suggest that tau plays a critical role in the
post-synaptic region in spite of the fact that the existence of
hyperphosphorylated 64 kDa tau in dendritic spines of rTg4510
mice has not yet been conclusively proven. On the other hand,
recent studies clarified that microtubule dynamics are essential
for the regulation of spine morphology (45–47). Microtubule
incursions into spines have been demonstrated in mature hip-
pocampal cultures, suggesting that tau can be released at the
plus-end of microtubules in spine. It was also reported that micro-
tubule affinity-regulating kinase is essential for maintaining spine
morphology (48). Therefore, the search for a transition mecha-
nism of tau into the post-synaptic region is a project of major
interest.
In conclusion, we observed that tau in the synaptosomal frac-
tion was less-phosphorylated than that in the cytosolic fraction,
and that synaptosomal tau distribution was induced by over-
expression of human P301L tau in a transgenic mouse model
of tauopathy. Although our data cannot determine whether the
detected tau is of pre-synaptic or post-synaptic origin, further
investigations will allow us to elucidate the critical role of tau in
synapse. Regulating the synaptosomal tau level might be a target
for therapeutic interventions to protect the formation of toxic tau
species inducing synaptic dysfunction.
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